SpineThera Granted U.S. Patent for its Platform Technology

SpineThera Inc. has been granted its seventh U.S. patent.

Patent No.12,144,819 covers key aspects of the company’s proprietary micro-suspension long-acting injectable technology. This innovation leverages a unique platform that allows for targeted, extended release of therapeutic agents, offering sustained effect with fewer side effects than existing treatments. By also reducing the need for frequent dosing, SpineThera’s platform is uniquely positioned to improve patient outcomes and address the urgent need for better treatment options.

“Securing our seventh patent is a testament to SpineThera’s ongoing commitment to innovative research and the development of breakthrough therapies that help patients,” SpineThera CEO Jeff Missling stated.

SpineThera’s latest patent enhances the protection of its core technology and supports its flagship product, SX-600, a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection (TF-EI) for the management of sciatica pain, currently in Ph II clinical development for patients suffering from sciatica.

The latest patent underscores SpineThera’s strategic focus on building a robust intellectual property portfolio to protect its current and future innovations. The company continues to explore additional indications and formulations that could further expand its market reach and improve quality of life for millions of patients worldwide.

SpineThera’s micro-suspension provides months long sustained-release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. The company is based in Plymouth, Minn.